Abivax S.a.
Clinical trials sponsored by Abivax S.a., explained in plain language.
-
New hope for ulcerative colitis: long-term drug shows promise
Disease control OngoingThis study looks at the long-term safety and effectiveness of a daily pill called ABX464 for people with moderate to severe ulcerative colitis. Participants had already seen improvement in a previous study and will take the drug for up to 54 months. The goal is to see if the drug…
Phase: PHASE2 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
New pill aims to keep ulcerative colitis in remission
Disease control OngoingThis study tests whether a daily dose of ABX464 (25 mg or 50 mg) can help people with moderate-to-severe ulcerative colitis stay in remission longer. About 1,100 participants who completed an earlier induction study will receive either ABX464 or a placebo for 44 weeks. The goal i…
Phase: PHASE3 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC